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Evidence indicates that cysteine proteases play essential role in malaria parasites; therefore an obvious area of investigation is the
inhibition of these enzymes to treat malaria. Studies with cysteine protease inhibitors and manipulating cysteine proteases genes
have suggested a role for cysteine proteases in hemoglobin hydrolysis. The best characterized Plasmodium cysteine proteases are
falcipains,whicharepapainfamilyenzymes.Falcipain-2andfalcipain-3aremajorhemoglobinasesofP.falciparum.Structuraland
functional analysis of falcipains showed that they have unique domains including a refolding domain and a hemoglobin binding
domain. Overall, the complexes of falcipain-2 and falcipain-3 with small and macromolecular inhibitors provide structural insight
to facilitate the design or modiﬁcation of eﬀective drug treatment against malaria. Drug development targeting falcipains should
be aided by a strong foundation of biochemical and structural studies.
1.Introduction
Malaria caused by Plasmodium falciparum is responsible for
880,000 deaths per year worldwide [1]. The regions where
malaria is endemic include Africa, Asia, and South America
[2]. A number of drugs are currently available to treat ma-
laria [3]; however, treatment is becoming complicated by
drug resistance, toxicity, and high cost. Recently, drug resis-
tance against the new eﬀective drug, artemisinin, is also
emerging [4, 5] ,a n dw en e e dn e we ﬀective drugs to treat
malaria. Therefore, the development of other classes of ef-
fective antimalarials, especially compounds that act against
novel biochemical targets, is required. To develop such com-
pounds, it is very important to characterize the structural
and biochemical features of new drug targets.
Amongpotentialnewtargetsforantimalarialchemother-
apy are Plasmodium proteases. Proteases are druggable tar-
gets, and at present protease inhibitors are now licensed as
well as in clinical development to treat diﬀerent diseases for
example osteoporosis, diabetes, cancer, hypertension, and
infectious diseases [6–9].
Recent advances, including the sequencing of Plasmod-
ium genomes (http://www.plasmodb.org/) and development
of new tools for manipulating Plasmodium genes [10], have
improvedourunderstanding ofthecysteineproteasesofpar-
asites. Therefore, given the importance of the cysteine pro-
teases,thispaperwillfocusonstructural-functionalrelation-
ship of falcipains, major cysteine proteases of P. falciparum.
In cases of malaria, the parasite relies on human hemo-
globin hydrolysis to supply amino acids for protein synthesis
andtomaintainosmoticstability[11,12].Cysteineproteases
are involved in hemoglobin hydrolysis and have been vali-
dated as promising drug targets [13, 14]. In a recent report,
Ch’ng et al., using cysteine protease inhibitors, demonstrate
that clan CA cysteine proteases of P. falciparum are also
involved in chloroquine-mediated programmed cell death
[15]. The best characterized Plasmodium cysteine proteases
are the falcipains, papain family (clan CA) enzymes (Figure
1).
Among the four P. falciparum cysteine proteases, falci-
pain-2 and falcipain-3 appear to be the principal food vac-
uolar hemoglobinases [16–18]. When the falcipain-2 gene
is disrupted, undegraded hemoglobin accumulates in the
food vacuole, conﬁrming that this enzyme participates in
haemoglobin hydrolysis [17]. However, disruption of falci-
pain-3 could not be achieved, but the gene was readily
replaced with a tagged functional copy, indicating that falci-
pain-3 is essential for erythrocytic parasites [18]. Falcipain-22 Journal of Tropical Medicine
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Figure 1: Falcipains have unique features. Falcipains are papain family cysteine proteases, active site residues (Cys, His, Asn) are conserved
within the papain family, but falcipains have a unique N-terminal extension acting as a refolding domain, and a C-terminal insert as a
hemoglobin (Hb) binding domain. Prodomain has ERFNIN and GNFD motifs, conserved in falcipains, papain, and cathepsin.
and falcipain-3 share 67% sequence identity and contribute
more or less equally to the digestion of hemoglobin in the
foodvacuole.Comparingwithotherpapainfamilyproteases,
falcipains contain unique domains (Figure 1). Speciﬁcally,
this paper will survey available information on structure and
function of diﬀerent domains of falcipain-2 and falcipain-3
and their interaction with inhibitors.
2.Domainsof Falcipains
2.1. The N-Terminal Part of the Prodomain Is Required for
Traﬃcking of Falcipains to the Food Vacuole. Falcipains are
major cysteine protease, named due to the function of
a catalytic cysteine, which mediates protein hydrolysis via
nucleophilic attack on the carbonyl carbon of a susceptible
peptide bond [19]. Falcipains have two main domains, the
prodomain and the mature domain. The prodomain is fur-
ther divided into diﬀerent small domains. At the N-terminus
of the prodomain, the ﬁrst 35 amino acids are cytosolic,
followed by a 20 amino acid transmembrane domain and a
188 amino acid lumenal domain. The inhibitory domain is
present in the C-terminal part of the prodomain (Figure 2).
Cysteine proteases of the parasite hydrolyze hemoglobin
in the acidic food vacuole [20, 21]. Recently, it has been
demonstrated that prodomain has unique motifs which are
responsible for targeting the falcipains. Using transfection
technology and constructing diﬀerent chimeras with por-
tions of the N-terminal part of prodomain fused to green
ﬂuorescent protein, it has been shown that the prodomains
of falcipain-2 and falcipain-3 were suﬃcient to target green
ﬂuorescent protein to the food vacuole. The transmembrane
domains of falcipain-2 and falcipain-3 are required for entry
into the ER. The absence of transmembrane domains led
to localization of GFP chimeras to the cytoplasm. Once
enzymes are in the ER, using the signal from transmembrane
domain, the proteins appear to traﬃc to the plasma mem-
brane. At the plasma membrane falcipain-2 and falcipain-3
appear to be endocytosed in a process requiring the presence
of both cytoplasmic and luminal prodomain traﬃcking
motifs, followed by vesicular transport to the food vacuole
[22].
In summary, serial truncation and deletion studies
showed that both a 20-amino acid stretch of the lumenal
portion and a 10-amino acid stretch of the cytoplasmic
portion of the enzymes were essential for food vacuolar
traﬃcking (Figure 3)[ 22].
2.2. The C-Terminal Part of the Prodomain Is Required for
I n h i b i t i n gt h eM a t u r eD o m a i n .Like many other proteases,
falcipains are synthesized as a zymogen, and the prodomain
inhibitstheactivityofthematureenzyme[23].Toinvestigate
how the prodomain regulates the activity of falcipain-2,
Pandey et al. expressed constructs encoding diﬀerent por-
tions of the prodomain and tested their ability to inhibit
recombinant mature falcipain-2. It has been found that
a C-terminal segment (Leu155–Asp243)o ft h ep r o d o m a i n ,
includingtwomotifs(ERFNINandGNFD)thatarealsocon-
served in cathepsin L subfamily proteases, mediates prodo-
main inhibitory activity [24].
Earlier work with other cathepsin L subfamily proteases
suggests key roles for conserved hydrophobic amino acids
(phenylalanine and tryptophan) as well as the ERFNIN and
GNFD motifs in maintaining prodomain structure [30].
Later, Pandey et al. explored the roles of conserved motifs
in maintaining prodomain structure by circular dichroism
analysis. Secondary structure was seen in a fragment with
potent inhibitory activity (Leu155–Asp243), but not in two
larger constructs that lacked any sequence downstream of
the ERFNIN and GNFD motifs or in a peptide spanning
the ERFNIN and GNFD motifs [24]. These results indicate
that, together with ERFNIN and GNFD motifs, an upstream
region including two conserved Phe∗ residues is required for
proper folding or maintenance of secondary structure of the
prodomain (Figure 2).
The 3D structures of the mature domain of falcipain-
2 and falcipain-3 have been solved [25, 26], andJournal of Tropical Medicine 3
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Figure 2: Domains of falcipain-2: schematic diagram showing diﬀerent domains of falcipain-2. Prodomain is made up of cytoplasmic,
transmembrane, luminal, and inhibitory domains. The mature domain has refolding domain, hemoglobin (Hb) binding domain, and
catalytic triad residues (Cys, His, Asn). The conserved residues (Phe165,P h e 168) present in inhibitory domain are labeled with asterisks.
Cyto TM
TM
TM
Lumenal
Lumenal
Lumenal
GFP
GFP
GFP
GFP
Cyto
Cyto
03 5 5 5 8 4 1 0 5
Yes
Yes
No
No
Construct Traﬃcking to the food vacuole
Figure 3: Schematic representation of the profalcipain-2-GFP constructs and their localization. Cytoplasmic (Cyto), transmembrane (TM),
and lumenal portions of the prodomain are labeled. Green ﬂuorescent protein is fused to study the traﬃcking of enzyme.
the profalcipain-2 model suggests that conserved residues
provide stability to the inhibitory domain (Figure 4(a)).
Modeling, based on the solved structure of procathepsin B
and procathepsin L [27, 28], shows that the charged pair
Arg185 and Glu221 of the prodomain appear to form a salt
bridge (Figure 4(b)). Further, Glu210 from the GNFD motif
may form a separate salt bridge with Lys403 in the mature
domain. Phe214 may participate in nonpolar interactions
and possibly pi stacking interactions, with two tryptophan
residuesinthematuredomain,Trp449 andTrp453.Themodel
also suggests that the prodomain of falcipain-2 binds the
mature domain in a manner similar to that of procathepsin
K and L, inhibiting catalytic activity by blocking substrate
access to the active site (Figure 4(a)).
2.3. The N-Terminal Part of the Mature Domain Is Required
for Refolding. Falcipain subfamily proteases have features
that are unusual for family C1A proteases. They encode
short N-terminal extensions of the mature domain, which
is unique among described papain family proteases [13, 14].
The N-terminal extensions allow folding of the mature
domain to active enzymes [29]. Other papain family en-
zymes required the prodomain for proper refolding [30].
Looking at the family of C1A cysteine protease sequences
on the Merops database (http://merops.sanger.ac.uk/)h a v e
identiﬁed more than 40 members with an N-terminus
extension of 12 amino acids at this location. Notably, 18 of
these sequences were those of falcipains and homologues
from other plasmodial species. It would be interesting to
ﬁnd out the role of those unique extensions.
To better characterize the determinants of folding for
falcipain-2, Pandey and Sijwali et al. expressed multiple
prodomain and mature constructs of the enzyme in E.
coli and assessed their abilities to refold by checking their
activity [23, 29]. This folding study showed that refolding
of the mature domain could be achieved when the mature
domainwascovalentlyjoinedwiththeN-terminusextension
(Figure 5). Only 12 amino acids of the N-terminus extension
(refolding domain) are necessary for refolding. Deletion of4 Journal of Tropical Medicine
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Figure 4: (a) Structure of profalcipain-2: The mature domain (magenta) of falcipain-2 was solved by X-ray diﬀraction. The active site
(catalytic triad residues in orange), refolding domain, and hemoglobin domain are labeled [25]. The prodomain (cyan) modeling was done
based on procathepsin L and K [24]. The prodomain runs up the face of the mature enzyme (purple) before formingα helices containing the
conserved ERFNIN and GNFD motifs (yellow). Since there is no homology, the 160 N-terminal residues of the prodomain are not included
in the prodomain model. (b) Prodomain-mature domain interactions. Closeup of predicted interactions between the mature domain
(magenta) and the ERFNIN (R185)a n dG N F D( E 210;F 214) motifs of prodomain (cyan). Blue dashed lines indicate presumed stabilizing
interactions (both electrostatic as well as hydrophobic) between residues [24].
12 amino acids from N-terminus segment of the mature
domain yielded a construct incapable of correct folding,
but inclusion of this segment in trans allowed folding to
active falcipain-2. Correct folding also occurred when the
catalytic domain was refolded with a separate prodomain-
folding domain construct but not with an isolated folding
domain peptide [23, 29]( Figure 5). These results indicated
that the prodomain mediates the interaction between the
mature and folding domain when they were not covalently
bound. However, it was not clear from these studies, whether
the amino-terminal extension is required only for folding
or whether it also plays an essential role in mediating
enzyme activity. To determine whether the folding domain
was required for activity, Pandey et al. incubated the mature
domain with the prodomain-folding domain in refolding
buﬀer.Afterrefoldingandpuriﬁcationofthematuredomain
by anion exchange chromatography, the puriﬁed refolded
mature domain still showed activity [29]. Together, these
results suggest that the refolding domain is only required for
refolding, and once refolding is accomplished, the refolding
domain is not required for activity [29].
The N-terminus extensions of diﬀerent falcipain sub-
family enzymes have limited (20–45%) sequence identity
but are functionally conserved. Chimeras of the falcipain-
2 catalytic domain with the refolding domain of six other
plasmodialproteasesfoldednormallyandhadsimilarkinetic
parameterstothoseofrecombinantfalcipain-2.Theseresults
showed that refolding domain can be swapped between
the plasmodial proteases that harbor the same function.
The above-mentioned experiment also indicates that all
plasmodial cysteine proteases including falcipain-3 also use
N-terminus extension as a refolding domain [29].
Structural analysis further reveals that the folding do-
main,infact,hasashortbutsigniﬁcantelementofsecondary
structure. Glutamate120 of the mature domain forms a
buried hydrogen bond with tyrosine13 and a salt bridge with
arginine5 of the refolding domain [25]. This suggests that
the small folding domain, though shorter than the standard
papain family prodomain, still plays a very important role
in folding by stabilizing the mature domain by a hydrogen
bond and a salt bridge [25]. This is analogous to a similar
interaction in falcipain-2, where tryosine12 of the refolding
domain of falcipain-3 provides hydrogen bonding anchor to
glutamate147 of the mature domain of falcipain-3 [26]. These
results indicate that the folding domains of falcipain-2 and
falcipain-3 stabilize the mature domain in a similar fashion.
2.4. The C-Terminus Insert as a Hemoglobin Binding Domain.
Falcipain-2and3eﬃcientlyhydrolyzehumanhemoglobinin
the acidic food vacuole of parasite [17, 18]. It has recently
been suggested that hemoglobin hydrolysis is not a highly
ordered process but rather proceeds with rapid cleavage by
falcipains at multiple sites [31]. Pandey et al. showed that
falcipains have a hemoglobin binding domain near the C-
terminus end [32]. Falcipain subfamily proteases contain an
unusualmotifneartheC-terminus,whichispresentbetween
the highly conserved active site histidine and asparagine
residues (Figure 2). A motif of identical size (14 aa) is
found in all studied proteases of this subfamily of falcipain,
although sequence identity is modest. In case of falcipain-2
andfalcipain-3,motifsaremadeupofa14residueβ-hairpin.
The secondary structure in this region is well conserved
between falcipain-2 and falcipain-3 [26]. Smaller motifs are
present in the sequences encoding P. falciparum serine repeatJournal of Tropical Medicine 5
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Figure 5: Expression and refolding of diﬀerent constructs of falcipain-2. Diﬀerent constructs were used to study refolding. The mature
domain was expressed alone or with the refolding domain either in cis or trans. In the last construct, folding of mature domain was done in
trans with profolding domain. After puriﬁcation of the mature domain, the activity was assayed [29].
antigens (10 aa) and dipeptidyl peptidase I (8 aa), and larger
(20 aa) motifs are present in two other putative P. falciparum
dipeptidyl peptidase genes [14, 33].
To evaluate the function of the unusual C-terminal motif
in falcipains, a mutant enzyme was made by deleting that
motif lacking 10 amino acids from falcipain-2, and the
biochemical properties of wild and mutant enzymes were
compared [32]. Native PAGE, Biacore, and gel ﬁltration
studiesindicatedthatthemotifmediatesspeciﬁcinteractions
with hemoglobin [32]. It has also been demonstrated by
other group that falcipain-2 also interacts with hemoglobin
[34]. In fact, falcipain-2 has relatively higher aﬃnity for
methemoglobin (kD is 0.8μM) than hemoglobin (kDa is
3.3μM) [34]. It had been demonstrated that several factors
contribute to the formation of methemoglobin during
malarial infection, including acidic pH of plasmodial food
vacuole, oxidative damage in RBC [35, 36], which causes
an increase in methemoglobin content to up to 20–42%
in the plasmodial food vacuole. Thus, the higher aﬃnity
of falcipain-2 for methemoglobin looks like an adapta-
tion to the speciﬁc conditions in the infected RBC. The
enzyme without this motif showed negligible activity against
hemoglobin or globin. Further, a peptide encoding the motif
blocked hemoglobin hydrolysis but not the hydrolysis of
casein, indicating that the motif speciﬁcally interacts with
hemoglobin [32]. Thus, this study suggests that the motif
mediates the most biologically relevant activity of falcipain,
the hydrolysis of hemoglobin during trophozoite stage.
Falcipains may also have other functions in erythrocytic
malaria parasites, and it would be interesting to explore the
role of the motif in hydrolysis of other proteins of potential
biological relevance. In the case of other members of the
falcipain subfamily, it is likely that the encoded motifs share
the same functions as the falcipain motif, because a number
of members of this subfamily have been also shown to
be hemoglobinases. The sequence conservation among the
motifs of falcipain subfamily proteases is not high, but, as in
the case of the N-terminal extension that mediates protein
folding, the presence of these unusual motifs in all related
proteases probably indicates a conserved function. For
genes encoding more distantly related enzymes, including
falcipain-1,dipeptidylpeptidases,andserinerepeatantigens,
C-terminal motifs vary greatly in sequence and size, and
speciﬁc functions of predicted motifs are undeﬁned. Data
indicates that falcipain-2 captures hemoglobin via its C-
terminal motif before subsequently cleaving the substrate at
multiple sites. Further, the structure of falcipain indicates
a protruding conﬁguration for the motif, surrounded by
a predominant negative charge [25], and it may be that
chargedresiduesarecrucialforinteractionwithhemoglobin.
It is proposed that hemoglobin, which has many charged
surface residues, ﬁrst binds at the motif through charge-
charge interaction and brings hemoglobin closer to the
active site before hydrolysis. The function of the motif in
mediating catalysis despite its separation from the active
site somewhat resembles that of the hemopexin domain of
matrix metalloproteases. The hemopexin domain is required
for both the eﬃcient cleavage of collagen [37] and the
formation of complexes with both inhibitors and proteases
to mediate biological activities [38]. Thus, as is the case6 Journal of Tropical Medicine
for the falcipain-2 motif, the hemopexin domain serves to
facilitate biologically relevant protein-substrate and protein-
inhibitor interactions. However, the hemopexin domain is
approximately 20 times larger than the falcipain motif and,
unlike the motif, is separated from the catalytic domain by a
hinge region. Therefore, it appears that falcipains and matrix
metalloproteases use similar means of biological control,
but the speciﬁc mechanisms by which the proteases mediate
interactions with substrates and inhibitors are diﬀerent.
Another papain family protease, cathepsin K, forms a
pentameric complex with chondroitin sulfate to facilitate
hydrolysis of collagen [39]. Having analogy to falcipain-2-
hemoglobin interaction, structural requirements for com-
plex formation between cathepsin K and chondroitin sulfate
are also required for hydrolysis of the biological substrate,
collagen. It is interesting to raise a question, why do falci-
pains contain a unique motif that mediates the hydrolysis
of hemoglobin? This mechanism might not have evolved
simply to facilitate hemoglobin hydrolysis, because other
papain family enzymes without C-terminus motifs still can
hydrolyze hemoglobin. It looks like that the utilization of
a speciﬁc motif at this region to mediate enzyme-substrate
interactionisanunusualbutconservedfeatureofplasmodial
cysteine proteases. It may be possible that an evolutionary
bottleneck occurred in ancestral plasmodial cysteine pro-
teases, and those enzymes might not be that eﬃcient in he-
moglobin hydrolysis. In addition, plasmodial cysteine pro-
teases might have evolved with introduction of speciﬁc motif
for eﬃcient hemoglobin hydrolysis.
The interaction of a major hemoglobinase, falcipain-
2, with most biologically relevant substrate, hemoglobin,
could be an interesting starting point for the development
of an eﬀective drug. The structure of falcipain-2 hemoglobin
binding domain will guide the design of inhibitors that
should interfere with hemoglobin binding.
3.StructuralBasisof Inhibitionof Falcipains
3.1.InhibitionofFalcipainsbyMacromolecules. Therearetwo
major classes of cysteine protease inhibitor, small inhibitors
like leupeptin, vinyl sulfones, E64, and another class known
as macromolecular inhibitor. Macromolecule inhibitors are
polypeptide in nature, which are generally present inside the
organisms. These endogenous cysteine protease inhibitors
have been described in a number of eukaryotic systems.
Here,wewilldiscussthreemajorcysteineproteaseinhibitors,
cystatin, chagasin, and falstatin.
3.1.1. Inhibition of Falcipains by Cystatin. Excluding the two
unique motifs discussed earlier, the rest of the falcipains
are structurally similar to homologous proteases in the pa-
pain family. Wang et al. studied the falcipain-cystatin inter-
actionsbysolvingthestructureofthiscomplex[25].Cystatin
was used as a falcipain inhibitor with the expectation that
protein-protein interaction over large surfaces would en-
hance crystal quality and thus facilitate structural deter-
mination. Cystatins inhibit a wide range of papain family
cysteine proteases with high aﬃnity making them ideal
candidates for cocrystallization with falcipain. Falcipain and
chicken egg white cystatin formed 1:1 complex (Figure
6(a)). The inhibitory constants (Ki) of cystatin for falcipain-
2 and falcipain-3 are 6.5nM and 100nM, respectively [25].
It is interesting that cystatin is a more potent inhibitor of
falcipain-2 than falcipain-3, which suggests that cystatin reg-
ulates both the falcipains with diﬀerent rates. This might
be important biologically, since their timing of expression
is slightly diﬀerent. The falcipain-cystatin complex shares
many features with two known cysteine protease-cystatin
structures: cathepsin H-steﬁn A and papain-steﬁn B (the
steﬁns are a subclass within the cystatin superfamily [41,
42]). These cystatins bind to target proteases in similar or-
ientations, resulting in extensive interactions with the tar-
get proteases (Figure 6(b)). Cystatin largely interacts with
falcipain-2 at prime sites where substrate-binding pockets
are relatively shallow and less deﬁned, but falcipains also
have binding speciﬁcity at nonprimed sites. Although, the
binding preference is not as pronounced as that found at the
S2 pocket (Figure 6(b)). Cystatin is only able to access the
solvent exposed periphery of the nonprime site of falcipain-
2 and majority of its binding occurs at the prime end of the
active site.
UnlikemostothercathepsinL-likecysteineproteases,fal-
cipain-2 strongly prefers a Leu at P2 over a Phe [43]. Crystal
structures indicate that this preference may be due to Ile68
in falcipains, because it creates a small protrusion in the
otherwise ﬂat base of the S2 pocket, which restricts aromatic
side-chain binding [25]( Figure 6(b)). The falcipain–cystatin
complex can be exploited to design potent inhibitors of the
malariaparasite.Arecentstudyindicatesthatapeptidebased
on cystatin binding residues blocked the activity of falcipain-
2 and led to accumulation of undegraded hemoglobin in the
food vacuole [44].
3.1.2. Inhibition of Falcipain by Chagasin. Chagasin is a cys-
teine protease inhibitor that was ﬁrst identiﬁed in Try-
panosoma cruzi as the physiological regulator of cruzain, the
major cysteine protease [45, 46]. Cruzain is also a papain-
like (Clan CA) cysteine protease that is expressed in all stages
of T. cruzi life cycle. It is a key virulence factor of T. cruzi,
the infectious agent responsible for the leading cause of heart
disease in Latin America, called the Chagas disease [47].
Chagasin is associated with cruzain during its traf-
ﬁcking to speciﬁc compartments of the parasite cell, and
accumulated evidence suggests that the primary role of
chagasinisinposttranslationalregulationofproteaseactivity
[45]. Chagasin is also a potent inhibitor of falcipains and
demonstrates 1:1 binding with falcipain-2 (Figure 7). The
protease-binding loops (BC, DE, and FG) in chagasin form
a well-aligned wedge that ﬁlls the active site groove of
falcipain-2 to obstruct substrate binding (Figure 7)[ 40].
The BC loop is one of the three signature motifs that
contribute to the inhibition of the cysteine protease. This is
conﬁrmed by a synthetic peptide corresponding to the BC
loop of the chagasin like protein from E. histolytica, which
speciﬁcally blocked the activity of cysteine proteases [49].
It is noteworthy that Thr 31 in the BC loop of chagasinJournal of Tropical Medicine 7
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Figure 6: (a) 3D structure of falcipain-2-cystatin complex. Cystatin is colored in orange, and falcipain-2 protease is colored in green.
Refolding domain and hemoglobin binding domain highlighted in pink and salmon, respectively. The shaded area in the ﬁgure corresponds
to the size of human cathepsin H, superimposed on falcipain-2 in light blue. (b) The catalytic Cys, His, and Asn are depicted in stick mode
in green, and substrate binding pockets are labeled P3 to P1 . Ile-68 at P2 is depicted in stick mode to illustrate a slight protrusion in the S2
pocket of falcipain-2.
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Figure 7: Structure of falcipain-2-chagasin complex: overall structure of chagasin with falcipain-2, chagasin in red and falcipain-2 in gold.
Key binding interactions between chagasin and falcipain-2 can be seen [40].
binds to the catalytic Cys at the falcipain-2 active site by
water-mediated hydrogen bonds (Figure 7). It is likely that
the highly conserved Thr serves as a key functional residue
among chagasin-like inhibitors. Another interesting feature
of the falcipain-2-chagasin interaction is the highly mobile
DE loop like in E64, a strong irreversible inhibitor of cysteine
protease, which occupies the nonprime site. In summary, the
BC loop, mobile DE loop, and the RPW/F motif in the FG
loop are the key elements for binding with falcipain-2.
3.1.3. Inhibition of Falcipain by Falstatin. Disturbance of
the equilibrium between cysteine proteases and natural
inhibitors is a key event in the pathogenesis of cancer,
rheumatoid arthritis, osteoporosis, and emphysema. In case
of malaria, falstatin has been recognized as an endogenous
cysteine protease inhibitor in P. falciparum. Erythrocytic P.
falciparum parasites express falstatin, a potent inhibitor of
falcipains and many other cysteine proteases [50]. But it is
unknown how falstatin regulate the P. falciparum cysteine8 Journal of Tropical Medicine
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Figure 9: Interaction between falcipain-2 and E-64. The residues in
the active site of falcipain-2 are colored blue and labeled, and E-64
is colored in grey. The interactions with enzyme and inhibitor are
in pink [26].
proteases.Thestage-speciﬁcityoffalstatinexpressionandthe
eﬀects of anti-falstatin antibodies on parasite development
suggest that this inhibitor facilitates a process that also
requires proteolytic activity, the invasion of erythrocytes
by P. falciparum merozoites. Falstatin is a competitive
and reversible inhibitor of falcipains, as demonstrated by
increasing calculated Km values but similar Vmax values with
increasing concentrations of falstatin [50].
Trp215
Gln45
Asn213
Asn182
Asn87
His183
Gly92
Gly91
Glu243
Tyr93
Ile94
3.2˚ A
Pro181
3 ˚ A
3 ˚ A
3 ˚ A
3.1 ˚ A
2.8 ˚ A
2.6 ˚ A
2.8 ˚ A
2.9 ˚ A
3.6 ˚ A
3.1 ˚ A
2.7 ˚ A 2.6 ˚ A
2.4 ˚ A
2.5 ˚ A
Figure 10: Interaction between falcipain 3-leupeptin: the residues
in the active site of falcipain-3 are colored yellow and labeled, and
leupeptin is colored in gray. The interactions with enzyme and
inhibitor are in pink [26].
To evaluate the mechanism of inhibition of cysteine
proteases by falstatin, Pandey et al. tested the ability of active
site-inhibited falcipain-2 to compete with active falcipain-
2 for binding with falstatin. In contrast to results with the
prodomain, the inhibitory eﬀect of falstatin was not aﬀected
by the presence of active site inhibited falcipain-2 [50]. Thus,
the binding of falstatin to falcipain-2 appears to be via
interaction with the enzyme active site.Journal of Tropical Medicine 9
Asn87
Gly92
Asn182
Glu243
Asn213
His183
Cys51
Gln45
Trp215
(a)
S3
S1
S1 
S2
(b)
Figure 11: (a) Interaction of falcipain-3 with morpholinourea-leucine-homophenylanyl-phenyl vinylsulfone (Mu-Leu-Hph-VsPh). The
residues in the active site of falcipain-3 are colored yellow and labeled, and morpholinourea-leucine-homophenylanyl-phenyl vinylsulfone is
colored gray. The interactions with enzyme and inhibitor are in black dots. (b) The active site of falcipain-3 with hydrophobic environment.
The inhibitor occupies the S1 , S1, S2, S3 subsites of enzyme. Hydrophobic residues are colored light green, and polar residues that interact
with the inhibitor by nonpolar C–C bonds are colored dark green [48].
3.2. Inhibition of Falcipains by Small Molecule Inhibitors
(Leupeptin, E-64, and Vinyl Sulfones). Leupeptin, E-64, and
vinylsulfonesaremajorcysteineproteaseinhibitorsthatbind
totheactivesite[26,48].Theacti v esit eso fbothe nzymesar e
located in a cleft between the structurally distinct domain
of the papain-like fold. The structures of falcipain-2 and
falcipain-3 have been determined in complex with these
small inhibitors. E-64, and leupeptin interact with residues
in the S1, S2, and S3 subsites of falcipain-2 and falcipain-
3, corresponding to the P1, and P2, and P3 position of the
inhibitors (Figure 8).
The conserved catalytic residues of falcipain-2 and
falcipain-3 (Gln 36/45,C y s42/51,H i s174/183,A s n204/213,r e s p . )
are similarly oriented with respect to the co-crystallized
inhibitors. Inhibitors display binding modes with their
partner enzymes similar to those found in other papain
family enzymes [26]. The inhibitors bind to the main chain
of falcipain-2 and falcipain-3 by glycine (Gly83 in falcipain-
2a n dG l y 92 in falcipain-3) residue that is highly conserved
in the S3 subsite of clan CA cysteine proteases (Figure 9).
In cocrystallization, these residues form hydrogen bonds
with the O and N atoms of the inhibitor backbone. In the
case of the falcipain-2 complex with E-64, enzyme active
sites Gln36,S e r 41,C y s 42,A s n 81,a n dH i s 174 are involved in
the formation of additional hydrogen bonds with E-64. In
the falcipain-3-leupeptin complex, Gln45,C y s 51,a n dA s n 182
also act as hydrogen bonding partners to the inhibitor. The
enzyme-inhibitor complex stabilize by a series of possible
hydrophobic interaction using nonpolar region of Gly40,
Tyr78,G l y 82,l e u 84,S e r 149,L e u 172,A s n 173,a n dA l a 175 in
falcipain-2, and Tyro90,G l y 91,T y r 93,I l e 94,a n dS e r 158 in case
of falcipain-3. The active site cysteine of falcipain-2 forms
a covalent, irreversible hemithioketal with the E-64 epoxy
carbon (Figure 9)[ 26].
The active site cysteine of falcipain-3 forms a covalent,
reversible hemithioacetal with the asymmetric carbonyl
carbonofleupeptin (Figure 10)[26].Theinteractionpattern
of E-64 and leupeptin with all papain family enzymes is
conserved. The carboxyl group of E-64 and carbonyl group
of leupeptin occupy the oxyanion hole formed by the con-
served catalytic residues. Falcipain-2 and Falcipain-3 have a
clear preference for substrates/inhibitors that contains a leu-
cine at P2 position, and both leupeptin and E64 contain a
Leu at P2. Surprisingly, falcipain-3 has been shown to be
much less eﬃcient at hydrolyzing peptide substrates and
more diﬃcult to inhibit with small peptidyl-based inhibitors
compared with falcipain-2 [16, 51].
The structure that forms the active site is highly con-
served between falcipain-2 and falcipain-3, and there is no
notable movement in the peptide backbone or loop region.
However, superimposition of falcipain-2 and falcipain-3
structures highlights two important substitutions in the S2
subsite. Falcipain-2 has Asp234 and Leu84, and falcipain-3
has Glu243 and Tyr93 [26]. This position of the S2 subsite
is known to be a key determiner of the speciﬁcity (Figures
9 and 10). In comparison to Asp234 in falcipain-2, the ad-
ditional side chain carbon in Glu243 of falcipain-3, this in-
creased the size as well as ﬂexibility at this position. In
case of falcipain-3–leupeptin complex, the larger and more
ﬂexibleresidue(Glu243)atthebottomofS2subsiteandbulk-
ier residue (Try93) create a narrow wall of the S2 subsite [26],
as compared to the falcipain–E-64 complex (Figure 10). The
overall structures of falcipain-3–leupeptin and falcipain-2–
E-64 complexes show a similar mode of binding and inhi-
bition compared with macromolecule inhibitors like cha-
gasin and cystatin.
Like E64 and leupeptin, vinyl sulphones (Mu-leu-Hph-
VsPh)havebeenshowntobeeﬀectiveinhibitorsofanumber
of papain-family-like cysteine proteases. Mu-Leu-Hph-VSPh
isapotentirreversibleinhibitoroffalcipain-2andfalcipain-3
[48]. The cocrystallization of falcipain-3 with Mu-Leu-Hph-
VsPh indicates that inhibitor binds the respective S1 and S3
subsitestoformanirreversible,covalentbondwiththesulfur
of the active site cysteine thiol in enzyme [48]( Figure 11).10 Journal of Tropical Medicine
Falcipain-3 prefers Leu at P2 of Mu-Leu-Hph-VsPh. Given
the hydrophobic nature of the P1 and P2 substituents in
Mu-leu-Hph-VsPh, the active site of falcipain-3 is lined with
a number of residues that are able to make nonpolar contacts
with their respective inhibitor [48]( Figure 11).
As seen in the crystal structures of falcipain-3 with the
above inhibitor, the residue at the bottom of the S2 subsite
(Glu243) points out of the pocket to avoid a potentially
unfavorable interaction with the bulky Phe residue at the
P2 position of inhibitor. Cysteine proteases of the malaria
parasite may be targeted for inhibition by vinyl sulphones.
Indeed, vinyl sulphones-based cysteine protease inhibitors
are already being used in preclinical trials for the Chagas
disease [52].
4. Summary and Conclusion
The understanding of the cysteine proteases of malaria
parasites has increased markedly in recent years. Since
cysteine proteases that play an important role in the
parasite life cycle by degrading erythrocyte proteins, most
notably hemoglobin, are attractive targets for antimalarial
chemotherapy. Falcipain-2 and falcipain-3 are the best char-
acterized cysteine proteases of malaria parasite, the structure
a n df u n c t i o no fd i ﬀerent domains and their interaction
with small and macromolecular inhibitors are studied. The
structure-function study of falcipains and interaction with
inhibitors will provide detail insights to develop ratio-
nal design of inhibitor against falcipains. Structure-guided
approaches should have great role in the design of potent
and highly selective inhibitor. Eﬀorts to optimize current
inhibitors based on the structure-function of falcipains are
currently underway.
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